At the end of the latest market close, Bristol-Myers Squibb Company (BMY) was valued at $61.43. In that particular session, Stock kicked-off at the price of $61.77 while reaching the peak value of $61.97 and lowest value recorded on the day was $61.13. The stock current value is $61.31.
Recently in News on December 23, 2020, Bristol Myers Squibb Announces Update on Phase 3 CheckMate -548 Trial Evaluating Patients with Newly Diagnosed MGMT-Methylated Glioblastoma Multiforme. Bristol Myers Squibb (NYSE: BMY) today announced an update on CheckMate -548, a Phase 3 trial evaluating the addition of Opdivo (nivolumab) to the current standard of care (temozolomide and radiation therapy) versus placebo plus the standard of care in patients with newly diagnosed glioblastoma multiforme (GBM) with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation following surgical resection of the tumor. Following a routine review of the study by an independent data monitoring committee (DMC), Bristol Myers Squibb was informed that based on the number of events to date, the study will not meet its primary endpoint of overall survival in patients with no baseline corticosteroid use or in the overall randomized population. The DMC indicated there were no safety concerns observed in patients treated with Opdivo that warranted stopping the study. You can read further details here
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free. .
Bristol-Myers Squibb Company had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $68.34 on 01/22/20, with the lowest value was $45.76 for the same time period, recorded on 03/23/20.
Bristol-Myers Squibb Company (BMY) full year performance was -2.82%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Bristol-Myers Squibb Company shares are logging -10.29% during the 52-week period from high price, and 33.98% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $45.76 and $68.34.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1558043 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Bristol-Myers Squibb Company (BMY) recorded performance in the market was -4.30%, having the revenues showcasing 4.14% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 137.54B, as it employees total of 30000 workers.
Specialists analysis on Bristol-Myers Squibb Company (BMY)
During the last month, 12 analysts gave the Bristol-Myers Squibb Company a BUY rating, 2 of the polled analysts branded the stock as an OVERWEIGHT, 6 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 61.21, with a change in the price was noted +2.33. In a similar fashion, Bristol-Myers Squibb Company posted a movement of +3.93% for the period of last 100 days, recording 10,314,730 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for BMY is recording 0.90 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.82.
Trends and Technical analysis: Bristol-Myers Squibb Company (BMY)
Raw Stochastic average of Bristol-Myers Squibb Company in the period of last 50 days is set at 49.29%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 39.40%. In the last 20 days, the company’s Stochastic %K was 44.55% and its Stochastic %D was recorded 57.64%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -4.30%. Additionally, trading for the stock in the period of the last six months notably improved by 6.35%, alongside a downfall of -2.82% for the period of the last 12 months. The shares increased approximately by -1.82% in the 7-day charts and went down by -0.29% in the period of the last 30 days. Common stock shares were driven by 4.14% during last recorded quarter.